Kulothungan Gunasekaran1, Dinesh C Voruganti2, Mandeep Singh Rahi1, Kalaimani Elango3, Sathishkumar Ramalingam4, Adiba Geeti1, Jeff Kwon1. 1. Division of Pulmonary Diseases and Critical Care Medicine, Yale-New Haven Health Bridgeport Hospital, Bridgeport, Connecticut, USA. 2. Division of Cardiovascular Medicine, The University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. 3. Division of Cardiology, University of Nevada Las Vegas, Las Vegas, Nevada, USA. 4. Division of Hospital Medicine, Lovelace Medical Center, Albuquerque, New Mexico, USA.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of mortality in the United States. Due to the ongoing legalization of cannabis, its acceptance, availability, and use in the in-patient population are on the rise. In this retrospective study, we investigated the association of cannabis use with important outcomes in COPD hospitalizations. Methods: The National Inpatient Sample (NIS) data were analyzed from 2005 to 2014. The primary outcome of interest was the trends and outcomes of cannabis use among COPD hospitalizations, including in-hospital mortality, pneumonia, sepsis, and respiratory failure. Results: We identified 6,073,862 hospitalizations, 18 years of age or older, with COPD using hospital discharge codes. Of these, 6,049,316 (99.6%) were without cannabis use, and 24,546 (0.4%) were admitted with cannabis use. The majority of COPD hospitalizations with cannabis use were aged 50-64 (60%). Cannabis use was associated with lower odds of in-hospital mortality (odds ratio [OR] 0.624 [95% confidence interval (CI) 0.407-0.958]; p=0.0309) and pneumonia (OR 0.882 [95% CI 0.806-0.964]; p=0.0059) among COPD hospitalizations. Cannabis use also had lower odds of sepsis (OR 0.749 [95% CI 0.523-1.071]; p=0.1127) and acute respiratory failure (OR 0.995 [95% CI 0.877-1.13]; p=0.9411), but it was not statistically significant. Conclusions: Among hospitalized patients with a diagnosis of COPD, cannabis users had statistically significant lower odds of in-hospital mortality and pneumonia compared to noncannabis users. The association between cannabis use and these favorable outcomes deserves further study to understand the interaction between cannabis use and COPD.
Background: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of mortality in the United States. Due to the ongoing legalization of cannabis, its acceptance, availability, and use in the in-patient population are on the rise. In this retrospective study, we investigated the association of cannabis use with important outcomes in COPD hospitalizations. Methods: The National Inpatient Sample (NIS) data were analyzed from 2005 to 2014. The primary outcome of interest was the trends and outcomes of cannabis use among COPD hospitalizations, including in-hospital mortality, pneumonia, sepsis, and respiratory failure. Results: We identified 6,073,862 hospitalizations, 18 years of age or older, with COPD using hospital discharge codes. Of these, 6,049,316 (99.6%) were without cannabis use, and 24,546 (0.4%) were admitted with cannabis use. The majority of COPD hospitalizations with cannabis use were aged 50-64 (60%). Cannabis use was associated with lower odds of in-hospital mortality (odds ratio [OR] 0.624 [95% confidence interval (CI) 0.407-0.958]; p=0.0309) and pneumonia (OR 0.882 [95% CI 0.806-0.964]; p=0.0059) among COPD hospitalizations. Cannabis use also had lower odds of sepsis (OR 0.749 [95% CI 0.523-1.071]; p=0.1127) and acute respiratory failure (OR 0.995 [95% CI 0.877-1.13]; p=0.9411), but it was not statistically significant. Conclusions: Among hospitalized patients with a diagnosis of COPD, cannabis users had statistically significant lower odds of in-hospital mortality and pneumonia compared to noncannabis users. The association between cannabis use and these favorable outcomes deserves further study to understand the interaction between cannabis use and COPD.
Entities:
Keywords:
COPD; National Inpatient Sample; cannabis; mortality; outcomes research; pneumonia
Authors: G C Baldwin; D P Tashkin; D M Buckley; A N Park; S M Dubinett; M D Roth Journal: Am J Respir Crit Care Med Date: 1997-11 Impact factor: 21.405
Authors: Paris Charilaou; Kanishk Agnihotri; Pablo Garcia; Apurva Badheka; Douglas Frenia; Balaji Yegneswaran Journal: Am J Med Date: 2017-02-02 Impact factor: 4.965
Authors: A B Thompson; G Huerta; R A Robbins; J H Sisson; J R Spurzem; S von Essen; K A Rickard; D J Romberger; I Rubinstein; M Ghafouri Journal: Chest Date: 1993-05 Impact factor: 9.410
Authors: Hyungjin Myra Kim; Eric G Smith; Claire M Stano; Dara Ganoczy; Kara Zivin; Heather Walters; Marcia Valenstein Journal: BMC Health Serv Res Date: 2012-01-23 Impact factor: 2.655
Authors: Dinesh C Voruganti; Ghanshyam Shantha; Sushma Dugyala; Naga Venkata K Pothineni; Deobrat Chandra Mallick; Abhishek Deshmukh; Ala Mohsen; Stephanie S Colello; Mohammed Saeed; Rakesh Latchamsetty; Krit Jongnarangsin; Frank Pelosi; Ryan M Carnahan; Michael Giudici Journal: BMC Res Notes Date: 2019-07-12